ASCO 2025: PharmaMar presented data showing that the combo of Zepzelca and Tecentriq significantly improved survival as first-line maintenance therapy for extensive-stage small cell lung cancer

Global Product Lead José Antonio López-Vilariño describes the data and VP of Strategic Development Pascal Besman puts the result in context of this cancer type and stage that historically has had a very poor prognosis.